Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Revvity to acquire Human Cell Design for drug discovery

PUBLIC · RVTYSep 09, 2026about 2 hours ago

Acquiring Company

Revvity

Acquired Company

Human Cell Design

WalthamFranceBiotechnologyCyber SecurityBiotechnology

Description

Revvity, Inc. has announced a definitive agreement to acquire Human Cell Design, a biotechnology firm based in France. This acquisition aims to enhance Revvity's Life Sciences portfolio by integrating HCD’s human pancreatic beta cell models. The move supports advancements in drug discovery, screening, and preclinical research.

Company Information

Company

Revvity

Location

Waltham, Massachusetts, United States

About

Revvity, Inc. is a global enterprise specializing in strategic and operational initiatives, scientific innovation, and complex global development, all with a deep commitment to sustainability and cybersecurity.

Don't miss Revvity's next move

Get an email the moment Revvity makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suvajit
Senior decision-maker at this company
••••••••@••••••••

See Suvajit's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Revvity's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Human Cell Design?

Human Cell Design was acquired by Revvity, based in Waltham. The deal was reported on September 9, 2026. Revvity, Inc. is a global enterprise specializing in strategic and operational initiatives, scientific innovation, and complex global development, all with a deep commitment to sustainability and cybersecurity. Revvity is publicly traded (RVTY) and operates in Biotechnology.

When did Revvity acquire Human Cell Design?

Revvity's acquisition of Human Cell Design was reported on September 9, 2026. Revvity, Inc. has announced a definitive agreement to acquire Human Cell Design, a biotechnology firm based in France. This acquisition aims to enhance Revvity's Life Sciences portfolio by integrating HCD’s human pancreatic beta cell models. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Human Cell Design do?

Human Cell Design is a biotechnology company that specializes in creating human cell models for research. The company's solutions are particularly focused on preclinical research for diabetes, obesity, and various metabolic diseases. It is privately held, operating in Biotechnology, and is based in France.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.